These findings prompt speculation that CD39 and CD73 may represent potential therapeutic targets in CTCL, and suggest that combining the targeting of the adenosine pathway, along with immune checkpoint inhibitors, may have synergistic anti-tumor effects and improve patient survival. This evidence concerns the gene ENTPD1 and primary cutaneous T-cell non-Hodgkin lymphoma.